The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms
Abstract
:1. Introduction
2. Primary Myelofibrosis
3. Secondary Myelofibrosis
4. Polycythemia Vera
5. Essential Thrombocytopenia
6. Other Ph-Myeloproliferative Neoplasms
6.1. Chronic Neutrophilic Leukemia (CNL)
6.2. Chronic Eosinophilic Leukemia, NOS (CEL, NOS)
6.3. Mastocytosis
6.4. Myeloproliferative Neoplasm, Unclassifiable
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127, 2391–2405. [Google Scholar] [CrossRef] [PubMed]
- Wolanskyj, A.P.; Lasho, T.L.; Schwager, S.M.; McClure, R.F.; Wadleigh, M.; Lee, S.J.; Gilliland, D.G.; Tefferi, A. JAK2V617F mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br. J. Haematol. 2005, 131, 208–213. [Google Scholar] [CrossRef]
- Chachoua, I.; Pecquet, C.; El-Khoury, M.; Nivarthi, H.; Albu, R.-I.; Marty, C.; Gryshkova, V.; Defour, J.-P.; Vertenoeil, G.; Ngo, A.; et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2016, 127, 1325–1335. [Google Scholar] [CrossRef] [PubMed]
- Cabagnols, X.; Favale, F.; Pasquier, F.; Messaoudi, K.; Defour, J.-P.; Ianotto, J.C.; Marzac, C.; Le Couédic, J.P.; Droin, N.; Chachoua, I.; et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 2016, 127, 333–342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maxson, J.E.; Gotlib, J.; Pollyea, D.A.; Fleischman, A.; Agarwal, A.; Eide, C.A.; Bottomly, D.; Wilmot, B.; McWeeney, S.; Tognon, C.E.; et al. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML. N. Engl. J. Med. 2013, 368, 1781–1790. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bayani, J.; Squire, J.A. Overview of Cytogenetic Chromosome Analysis. Curr. Protoc. Cell Biol. 2004, 23, 22.1.1–22.1.3. [Google Scholar] [CrossRef] [PubMed]
- Thoennissen, N.H.; Krug, U.O.; Lee, D.H.T.; Kawamata, N.; Iwanski, G.B.; Lasho, T.; Weiss, T.; Nowak, D.; Koren-Michowitz, M.; Kato, M.; et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010, 115, 2882–2890. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spivak, J.L. Myeloproliferative Neoplasms. N. Engl. J. Med. 2017, 376, 2168–2181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tefferi, A. Myelofibrosis with Myeloid Metaplasia. N. Engl. J. Med. 2000, 342, 1255–1265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tefferi, A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am. J. Hematol. 2021, 96, 145–162. [Google Scholar] [CrossRef]
- Barosi, G.; Tefferi, A.; Besses, C.; Birgegard, G.; Cervantes, F.; Finazzi, G.; Gisslinger, H.; Griesshammer, M.; Harrison, C.N.; Hehlmann, R.; et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia 2015, 29, 20–26. [Google Scholar] [CrossRef] [PubMed]
- Cervantes, F.; Passamonti, F.; Barosi, G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008, 22, 905–914. [Google Scholar] [CrossRef] [Green Version]
- Cervantes, F.; Dupriez, B.; Pereira, A.; Passamonti, F.; Reilly, J.T.; Morra, E.; Vannucchi, A.M.; Mesa, R.A.; Demory, J.-L.; Barosi, G.; et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113, 2895–2901. [Google Scholar] [CrossRef]
- Passamonti, F.; Cervantes, F.; Vannucchi, A.M.; Morra, E.; Rumi, E.; Pereira, A.; Guglielmelli, P.; Pungolino, E.; Caramella, M.; Maffioli, M.; et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115, 1703–1708. [Google Scholar] [CrossRef] [PubMed]
- Hussein, K.; Pardanani, A.D.; Van Dyke, D.L.; Hanson, C.A.; Tefferi, A. International Prognostic Scoring System–independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010, 115, 496–499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caramazza, D.; Begna, K.H.; Gangat, N.; Vaidya, R.; Siragusa, S.; Van Dyke, D.L.; Hanson, C.; Pardanani, A.; Tefferi, A. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2010, 25, 82–88. [Google Scholar] [CrossRef]
- Tefferi, A.; Jimma, T.; Gangat, N.; Vaidya, R.; Begna, K.H.; Hanson, C.A.; Van Dyke, D.L.; Caramazza, D.; Pardanani, A. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: A Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011, 118, 4595–4598. [Google Scholar] [CrossRef] [PubMed]
- Reilly, J.T. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia 2008, 22, 1818–1827. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hussein, K.; Van Dyke, D.L.; Tefferi, A. Conventional cytogenetics in myelofibrosis: Literature review and discussion. Eur. J. Haematol. 2009, 82, 329–338. [Google Scholar] [CrossRef] [PubMed]
- Tefferi, A.; Mesa, R.A.; Schroeder, G.; Hanson, C.A.; Li, C.-Y.; Dewald, G.W. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 2001, 113, 763–771. [Google Scholar] [CrossRef] [PubMed]
- Hussein, K.; Huang, J.; Lasho, T.; Pardanani, A.; Mesa, R.A.; Williamson, C.M.; Ketterling, R.P.; Hanson, C.A.; Van Dyke, D.L.; Tefferi, A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur. J. Haematol. 2009, 82, 255–259. [Google Scholar] [CrossRef] [PubMed]
- Reilly, J.T.; Snowden, J.A.; Spearing, R.L.; Fitzgerald, P.M.; Jones, N.; Watmore, A.; Potter, A. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. Br. J. Haematol. 1997, 98, 96–102. [Google Scholar] [CrossRef] [Green Version]
- Dupriez, B.; Morel, P.; Demory, J.; Lai, J.; Simon, M.; Plantier, I.; Bauters, F. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 1996, 88, 1013–1018. [Google Scholar] [CrossRef] [Green Version]
- Djordjević, V.; Dencic-Fekete, M.; Jovanovic, J.; Bizic, S.; Jankovic, G.; Bogdanovic, A.; Cemerikic-Martinovic, V.; Gotic, M. Cytogenetics of agnogenic myeloid metaplasia: A study of 61 patients. Cancer Genet. Cytogenet. 2007, 173, 57–62. [Google Scholar] [CrossRef]
- Demory, J.; Dupriez, B.; Fenaux, P.; Lai, J.; Beuscart, R.; Jouet, J.; Deminatti, M.; Bauters, F. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: A report on 47 cases. Blood 1988, 72, 855–859. [Google Scholar] [CrossRef]
- Miller, J.B.; Testa, J.R.; Lindgren, V.; Rowley, J.D. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 1985, 55, 582–591. [Google Scholar] [CrossRef]
- Smadja, N.; Krulik, M.; De Gramont, A.; Sirinelli, A.; Brissaud, P.; Dray, C.; Audebert, A.A.; Debray, J. Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia. Cancer Genet. Cytogenet. 1987, 24, 151–158. [Google Scholar] [CrossRef]
- Hidaka, T.; Shide, K.; Shimoda, H.; Kameda, T.; Toyama, K.; Katayose, K.; Kubuki, Y.; Nagata, K.; Takenaka, K.; Akashi, K.; et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: A prospective survey of 202 cases in Japan. Eur. J. Haematol. 2009, 83, 328–333. [Google Scholar] [CrossRef]
- Tam, C.S.; Abruzzo, L.V.; Lin, K.I.; Cortes, J.; Lynn, A.; Keating, M.J.; Thomas, D.A.; Pierce, S.; Kantarjian, H.; Verstovsek, S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 2009, 113, 4171–4178. [Google Scholar] [CrossRef] [Green Version]
- Mesa, R.A.; Li, C.-Y.; Ketterling, R.; Schroeder, G.S.; Knudson, R.A.; Tefferi, A. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005, 105, 973–977. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elena, C.; Passamonti, F.; Rumi, E.; Malcovati, L.; Arcaini, L.; Boveri, E.; Merli, M.; Pietra, D.; Pascutto, C.; Lazzarino, M. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2010, 96, 167–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gangat, N.; Caramazza, D.; Vaidya, R.; George, G.; Begna, K.; Schwager, S.; Van Dyke, D.; Hanson, C.; Wu, W.; Pardanani, A.; et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. J. Clin. Oncol. 2011, 29, 392–397. [Google Scholar] [CrossRef] [PubMed]
- Tefferi, A.; Nicolosi, M.; Mudireddy, M.; Lasho, T.L.; Gangat, N.; Begna, K.H.; Hanson, C.A.; Ketterling, R.P.; Pardanani, A. Revised cytogenetic risk stratification in primary myelofibrosis: Analysis based on 1002 informative patients. Leukemia 2018, 32, 1189–1199. [Google Scholar] [CrossRef] [PubMed]
- Guglielmelli, P.; Lasho, T.L.; Rotunno, G.; Mudireddy, M.; Mannarelli, C.; Nicolosi, M.; Pacilli, A.; Pardanani, A.; Rumi, E.; Rosti, V.; et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J. Clin. Oncol. 2018, 36, 310–318. [Google Scholar] [CrossRef] [PubMed]
- Tefferi, A.; Guglielmelli, P.; Lasho, T.L.; Gangat, N.; Ketterling, R.P.; Pardanani, A.; Vannucchi, A.M. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J. Clin. Oncol. 2018, 36, 1769–1770. [Google Scholar] [CrossRef]
- Tefferi, A.; Guglielmelli, P.; Nicolosi, M.; Mannelli, F.; Mudireddy, M.; Bartalucci, N.; Finke, C.M.; Lasho, T.L.; Hanson, C.A.; Ketterling, R.P.; et al. GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 2018, 32, 1631–1642. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andrieux, J.; Demory, J.L.; Caulier, M.T.; Agape, P.; Wetterwald, M.; Bauters, F.; Laï, J.L. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet. Cytogenet. 2003, 140, 118–123. [Google Scholar] [CrossRef]
- Dingli, D.; Schwager, S.M.; Mesa, R.A.; Li, C.-Y.; Dewald, G.W.; Tefferi, A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer 2006, 106, 1985–1989. [Google Scholar] [CrossRef] [PubMed]
- Hernández-Boluda, J.-C.; Pereira, A.; Correa, J.-G.; Alvarez-Larrán, A.; Ferrer-Marín, F.; Raya, J.-M.; Martínez-López, J.; Pérez-Encinas, M.; Estrada, N.; Velez, P.; et al. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia 2018, 32, 553–555. [Google Scholar] [CrossRef]
- Palandri, F.; Palumbo, G.A.; Iurlo, A.; Polverelli, N.; Benevolo, G.; Breccia, M.; Abruzzese, E.; Tiribelli, M.; Bonifacio, M.; Tieghi, A.; et al. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. Semin. Hematol. 2018, 55, 248–255. [Google Scholar] [CrossRef]
- Tefferi, A.; Guglielmelli, P.; Larson, D.R.; Finke, C.; Wassie, E.A.; Pieri, L.; Gangat, N.; Fjerza, R.; Belachew, A.A.; Lasho, T.L.; et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014, 124, 2507–2513. [Google Scholar] [CrossRef] [PubMed]
- Tefferi, A.; Barbui, T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am. J. Hematol. 2020, 95, 1599–1613. [Google Scholar] [CrossRef]
- Gangat, N.; Strand, J.J.; Lasho, T.L.; Finke, C.M.; Knudson, R.A.; Pardanani, A.D.; Li, C.-Y.; Ketterling, R.; Tefferi, A. Cytogenetic studies at diagnosis in polycythemia vera: Clinical and JAK2V617F allele burden correlates. Eur. J. Haematol. 2007, 80, 197–200. [Google Scholar] [CrossRef] [PubMed]
- Swolin, B.; Weinfeld, A.; Westin, J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988, 72, 386–395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tefferi, A.; Rumi, E.; Finazzi, G.; Gisslinger, H.; Vannucchi, A.M.; Rodeghiero, F.; Randi, M.L.; Vaidya, R.; Cazzola, M.; Rambaldi, A.; et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 2013, 27, 1874–1881. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barraco, D.; Cerquozzi, S.; Hanson, C.A.; Ketterling, R.P.; Pardanani, A.D.; Gangat, N.; Tefferi, A. Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. Br. J. Haematol. 2018, 182, 437–440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sever, M.; Quintás-Cardama, A.; Pierce, S.; Zhou, L.; Kantarjian, H.; Verstovsek, S. Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk. Lymphoma 2013, 54, 2667–2670. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Díez-Martín, J.L.; Graham, D.L.; Petitt, R.M.; Dewald, G.W. Chromosome Studies in 104 Patients With Polycythemia Vera. Mayo Clin. Proc. 1991, 66, 287–299. [Google Scholar] [CrossRef]
- Lawler, S.D. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera. Clin. Haematol. 1980, 9, 159–174. [Google Scholar] [CrossRef]
- Tang, G.; Lopez, J.E.H.; Wang, S.A.; Hu, S.; Ma, J.; Pierce, S.; Zuo, W.; Carballo-Zarate, A.A.; Yin, C.C.; Tang, Z.; et al. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 2017, 102, 1511–1518. [Google Scholar] [CrossRef] [Green Version]
- Tefferi, A.; Guglielmelli, P.; Lasho, T.L.; Coltro, G.; Finke, C.M.; Loscocco, G.G.; Sordi, B.; Szuber, N.; Rotunno, G.; Pacilli, A.; et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br. J. Haematol. 2020, 189, 291–302. [Google Scholar] [CrossRef]
- Tefferi, A.; Pardanani, A. Myeloproliferative Neoplasms. JAMA Oncol. 2015, 1, 97–105. [Google Scholar] [CrossRef] [PubMed]
- Elala, Y.C.; Lasho, T.L.; Gangat, N.; Finke, C.; Barraco, D.; Haider, M.; Hussein, A.K.A.; Hanson, C.A.; Ketterling, R.; Pardanani, A.; et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am. J. Hematol. 2016, 91, 503–506. [Google Scholar] [CrossRef] [Green Version]
- Beer, P.A.; Campbell, P.J.; Scott, L.M.; Bench, A.J.; Erber, W.N.; Bareford, D.; Wilkins, B.S.; Reilly, J.T.; Hasselbalch, H.C.; Bowman, R.; et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 2008, 112, 141–149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vannucchi, A.M.; Antonioli, E.; Guglielmelli, P.; Pardanani, A.; Tefferi, A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia 2008, 22, 1299–1307. [Google Scholar] [CrossRef] [PubMed]
- Lasho, T.L.; Finke, C.M.; Tischer, A.; Pardanani, A.; Tefferi, A. Mayo CALR mutation type classification guide using alpha helix propensity. Am. J. Hematol. 2018, 93, E128–E129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tefferi, A.; Wassie, E.A.; Guglielmelli, P.; Gangat, N.; Belachew, A.A.; Lasho, T.L.; Finke, C.; Ketterling, R.; Hanson, C.A.; Pardanani, A.; et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am. J. Hematol. 2014, 89, E121–E124. [Google Scholar] [CrossRef] [PubMed]
- Vannucchi, A.M.; Antonioli, E.; Guglielmelli, P.; Pancrazzi, A.; Guerini, V.; Barosi, G.; Ruggeri, M.; Specchia, G.; Lo-Coco, F.; Delaini, F.; et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008, 112, 844–847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Szuber, N.; Hanson, C.A.; Lasho, T.L.; Finke, C.; Ketterling, R.P.; Pardanani, A.; Gangat, N.; Tefferi, A. MPL-mutated essential thrombocythemia: A morphologic reappraisal. Blood Cancer J. 2018, 8, 1–6. [Google Scholar] [CrossRef]
- Feenstra, J.D.M.; Nivarthi, H.; Gisslinger, H.; Leroy, E.; Rumi, E.; Chachoua, I.; Bagienski, K.; Kubesova, B.; Pietra, D.; Gisslinger, B.; et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 2016, 127, 325–332. [Google Scholar] [CrossRef] [PubMed]
- Bacher, U.; Haferlach, T.; Kern, W.; Hiddemann, W.; Schnittger, S.; Schoch, C. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann. Hematol. 2005, 84, 250–257. [Google Scholar] [CrossRef] [PubMed]
- Gangat, N.; Tefferi, A.; Thanarajasingam, G.; Patnaik, M.; Schwager, S.; Ketterling, R.; Wolanskyj, A.P. Cytogenetic abnormalities in essential thrombocythemia: Prevalence and prognostic significance. Eur. J. Haematol. 2009, 83, 17–21. [Google Scholar] [CrossRef] [PubMed]
- Hsiao, H.-H.; Ito, Y.; Sashida, G.; Ohyashiki, J.H.; Ohyashiki, K. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Leuk. Res. 2005, 29, 1247–1252. [Google Scholar] [CrossRef] [PubMed]
- Panani, A.D. Cytogenetic findings in untreated patients with essential thrombocythemia. In Vivo 2006, 20, 381–384. [Google Scholar] [PubMed]
- Sessarego, M.; Defferrari, R.; Dejana, A.M.; Rebuttato, A.M.; Fugazza, G.; Salvidio, E.; Ajmar, F. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation: A 12-year study. Cancer Genet. Cytogenet. 1989, 43, 57–65. [Google Scholar] [CrossRef]
- Sever, M.; Kantarjian, H.; Pierce, S.; Jain, N.; Estrov, Z.; Cortes, J.; Verstovsek, S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int. J. Hematol. 2009, 90, 522–525. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bench, A.J.; Nacheva, E.P.; Champion, K.M.; Green, A.R. 7 Molecular genetics and cytogenetics of myeloproliferative disorders. Baillière’s Clin. Haematol. 1998, 11, 819–848. [Google Scholar] [CrossRef]
- Panani, A.D. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications. Cancer Lett. 2007, 255, 12–25. [Google Scholar] [CrossRef]
- Uppal, G.; Gong, J. Chronic neutrophilic leukaemia. J. Clin. Pathol. 2015, 68, 680–684. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reilly, J.T. Chronic neutrophilic leukaemia: A distinct clinical entity? Br. J. Haematol. 2002, 116, 10–18. [Google Scholar] [CrossRef]
- Orazi, A.; Cattoretti, G.; Sozzi, G. A Case of Chronic Neutrophilic Leukemia with Trisomy 8. Acta Haematol. 1989, 81, 148–151. [Google Scholar] [CrossRef]
- Hasle, H.; Olesen, G.; Kerndrup, G.; Philip, P.; Jacobsen, N. Chronic neutrophil leukaemia in adolescence and young adulthood. Br. J. Haematol. 1996, 94, 628–630. [Google Scholar] [CrossRef] [PubMed]
- Terré, C.; Garcia, I.; Bastie, J.N.; Mayeur, D.; Decombe, L.; Gruyer, P.; Berger, R.; Castaigne, S. A Case of Chronic Neutrophilic Leukemia with Deletion (11)(q23). Cancer Genet. Cytogenet. 1999, 110, 70–71. [Google Scholar] [CrossRef]
- Matano, S.; Nakamura, S.; Kobayashi, K.; Yoshida, T.; Matsuda, T.; Sugimoto, T. Deletion of the long arm of chromosome 20 in a patient with chronic neutrophilic leukemia: Cytogenetic findings in chronic neutrophilic leukemia. Am. J. Hematol. 1997, 54, 72–75. [Google Scholar] [CrossRef]
- Wang, S.A.; Hasserjian, R.P.; Tam, W.; Tsai, A.; Geyer, J.T.; George, T.; Foucar, K.; Rogers, H.J.; Hsi, E.D.; Rea, B.A.; et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica 2017, 102, 1352–1360. [Google Scholar] [CrossRef] [Green Version]
- Valent, P.; Akin, C.; Metcalfe, D.D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017, 129, 1420–1427. [Google Scholar] [CrossRef] [PubMed]
- Bain, B.J. Systemic mastocytosis and other mast cell neoplasms. Br. J. Haematol. 1999, 106, 9–17. [Google Scholar] [CrossRef] [Green Version]
- Lishner, M.; Confinocohen, R.; Mekori, Y.; Feigin, M.; Manor, Y.; Goldberg, A.; Ravid, M.; Amiel, A. Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis. J. Allergy Clin. Immunol. 1996, 98, 199–204. [Google Scholar] [CrossRef]
- Swolin, B.; Rodjer, S.; Roupe, G. Cytogenetic studies and in vitro colony growth in patients with mastocytosis. Blood 1987, 70, 1928–1932. [Google Scholar] [CrossRef] [Green Version]
- Swolin, B.; Rödjer, S.; Roupe, G. Cytogenetic Studies in Patients with Mastocytosis. Cancer Genet. Cytogenet. 2000, 120, 131–135. [Google Scholar] [CrossRef]
- Naumann, N.; Jawhar, M.; Schwaab, J.; Kluger, S.; Lübke, J.; Metzgeroth, G.; Popp, H.D.; Khaled, N.; Horny, H.-P.; Sotlar, K.; et al. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosom. Cancer 2018, 57, 252–259. [Google Scholar] [CrossRef] [Green Version]
- Shah, S.; Pardanani, A.; Elala, Y.C.; Lasho, T.L.; Patnaik, M.M.; Reichard, K.K.; Hanson, C.A.; Ketterling, R.P.; Tefferi, A. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. Am. J. Hematol. 2018, 93, 1461–1466. [Google Scholar] [CrossRef] [Green Version]
- Borovecki, A.; Skrtić, A.; Paro, M.M.K.; Lasan, R.; Dominis, M. The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features. Acta Med. Croat. 2011, 65, 31–36. [Google Scholar]
- Santana-Davila, R.; Tefferi, A.; Holtan, S.G.; Ketterling, R.P.; Dewald, G.W.; Knudson, R.A.; Steensma, D.P.; Chen, D.; Hoyer, J.D.; Hanson, C.A. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases. Leuk. Res. 2008, 32, 1927–1930. [Google Scholar] [CrossRef] [PubMed]
- Hahm, C.; Huh, H.J.; Mun, Y.-C.; Seong, C.M.; Chung, W.S.; Huh, J. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. Int. J. Lab. Hematol. 2015, 37, 181–189. [Google Scholar] [CrossRef] [PubMed]
- Chamseddine, A.N.; Etancelin, P.; Penther, D.; Parmentier, F.; Kuadjovi, C.; Camus, V.; Contentin, N.; Lenain, P.; Bastard, C.; Tilly, H.; et al. Transformation of an Unclassified Myeloproliferative Neoplasm with a RareBCR-JAK2Fusion Transcript Resulting from the Translocation (9;22)(p24;q11). Case Rep. Hematol. 2015, 2015, 1–5. [Google Scholar] [CrossRef] [Green Version]
- Mrózek, K.; Heerema, N.A.; Bloomfield, C.D. Cytogenetics in acute leukemia. Blood Rev. 2004, 18, 115–136. [Google Scholar] [CrossRef]
- Greenberg, P.L.; Tuechler, H.; Schanz, J.; Sanz, G.; Garcia-Manero, G.; Solé, F.; Bennett, J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F.; et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood 2012, 120, 2454–2465. [Google Scholar] [CrossRef] [PubMed]
- Behjati, S.; Tarpey, P.S. What is next generation sequencing? Arch. Dis. Child. Educ. Pr. Ed. 2013, 98, 236–238. [Google Scholar] [CrossRef]
- Nischal, S.; Bhattacharyya, S.; Christopeit, M.; Yu, Y.; Zhou, L.; Bhagat, T.D.; Sohal, D.; Will, B.; Mo, Y.; Suzuki, M.; et al. Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms. Cancer Res. 2013, 73, 1076–1085. [Google Scholar] [CrossRef] [Green Version]
- Mukherjee, S.; Sathanoori, M.; Ma, Z.; Andreatta, M.; Lennon, P.A.; Wheeler, S.R.; Prescott, J.L.; Coldren, C.; Casey, T.; Rietz, H.; et al. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies. Cancer Genet. 2017, 216–217, 128–141. [Google Scholar] [CrossRef] [PubMed]
WHO 2016 Myeloid Neoplasm and Acute Leukemia Classification |
Myeloproliferative neoplasms (MPN) |
○ Chronic myeloid leukemia (CML), BCR-ABL1+ |
○ Chronic neutrophilic leukemia (CNL) |
○ Polycythemia vera (PV) |
○ Primary myelofibrosis (PMF) |
○ PMF, prefibrotic/early stage |
○ PMF, overt fibrotic stage |
Essential thrombocythemia (ET) |
○ Chronic eosinophilic leukemia, not otherwise specified (NOS) |
○ MPN, unclassifiable |
Mastocytosis |
Diagnosis | Frequent Cytogenetic Alterations | References |
---|---|---|
PMF | Del(20q) Del(13q), chromosome 1 abnormalities | [20,21,22] |
PPV-MF/PET-MF | Chromosome 1 abnormalities Del(20q) | [37,38] |
Polycythemia vera | Del(20q) +8 +9 | [50] |
Essential thrombocythemia | Del(20q) Del(13q) +8 +9 | [67,68] |
Chronic Neutrophilic Leukemia | Del(20q) Del(11q) +8 +21 | [70,71,72,73,74] |
Chronic Eosinophilic Leukemia | +8 +15 Del(5q) i(17q) −7 | [75] |
Mastocytosis | Del(20q) Del(11q) Del(7q) | [80] |
Myeloproliferative neoplasm, Unclassifiable | +8 Del(5q) | [83,84] |
When to Perform Cytogenetics | Diagnosis | Routine BM Examination, If Performed | Time of Suspected Transformation |
---|---|---|---|
Myelofibrosis | Always if feasible | Always if feasible | Always if feasible |
Polycythemia vera | Always if feasible | No | Always if feasible |
Essential thrombocythemia | Always if feasible | No | Always if feasible |
Chronic Neutrophilic Leukemia | Always if feasible | No | Always if feasible |
Chronic Eosinophilic Leukemia | Always if feasible | No | Always if feasible |
Mastocytosis | Always if feasible | No | Always if feasible |
Myeloproliferative neoplasm, Unclassifiable | Always if feasible | No | Always if feasible |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lanzarone, G.; Olivi, M. The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina 2021, 57, 813. https://doi.org/10.3390/medicina57080813
Lanzarone G, Olivi M. The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina. 2021; 57(8):813. https://doi.org/10.3390/medicina57080813
Chicago/Turabian StyleLanzarone, Giuseppe, and Matteo Olivi. 2021. "The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms" Medicina 57, no. 8: 813. https://doi.org/10.3390/medicina57080813